BSP:A1RG34 (Netherlands)
Business Description
argenx SE
Willemstraat 5, Breda, NLD, 4811 AH
Compare
Compare
Traded in other countries / regions
ARGX.Austria
•
ARGX.Belgium
•
A1RG34.Brazil
•
1AE.Germany
•
0QW0.UK
•
ARGNF.USA
Description
argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 267.77 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 44 | |||||
| Beneish M-Score | 8.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 137.2 | |||||
| 3-Year EBITDA Growth Rate | -35.8 | |||||
| 3-Year EPS without NRI Growth Rate | -52.3 | |||||
| 3-Year FCF Growth Rate | -97.4 | |||||
| 3-Year Book Growth Rate | 42.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.21 | |||||
| 9-Day RSI | 52.27 | |||||
| 14-Day RSI | 52.98 | |||||
| 6-1 Month Momentum % | 35.6 | |||||
| 12-1 Month Momentum % | 25.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.07 | |||||
| Quick Ratio | 10.56 | |||||
| Cash Ratio | 9.82 | |||||
| Days Inventory | 5523.03 | |||||
| Days Sales Outstanding | 146.7 | |||||
| Days Payable | 10917.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.8 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 94.84 | |||||
| Operating Margin % | -665 | |||||
| Net Margin % | -708.65 | |||||
| ROE % | -33.17 | |||||
| ROA % | -30.12 | |||||
| ROIC % | -212.17 | |||||
| ROC (Joel Greenblatt) % | -2366.79 | |||||
| ROCE % | -32.16 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 168.61 | |||||
| PB Ratio | 7.31 | |||||
| Price-to-Tangible-Book | 7.75 | |||||
| EV-to-EBIT | -22.74 | |||||
| EV-to-Forward-EBIT | -24.12 | |||||
| EV-to-EBITDA | -22.9 | |||||
| EV-to-Forward-EBITDA | -24.32 | |||||
| EV-to-Revenue | 157.15 | |||||
| EV-to-Forward-Revenue | 40.67 | |||||
| EV-to-FCF | -22.36 | |||||
| Price-to-Net-Current-Asset-Value | 8.18 | |||||
| Price-to-Net-Cash | 9.36 | |||||
| Earnings Yield (Greenblatt) % | -4.4 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 649.732 | ||
| EPS (TTM) (R$) | -92.988 | ||
| Beta | 0 | ||
| Volatility % | 51.6 | ||
| 14-Day RSI | 52.98 | ||
| 14-Day ATR (R$) | 0.551556 | ||
| 20-Day SMA (R$) | 77.104 | ||
| 12-1 Month Momentum % | 25.08 | ||
| 52-Week Range (R$) | 55.58 - 81.2 | ||
| Shares Outstanding (Mil) | 55.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
argenx SE Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||